HOME >> BIOLOGY >> NEWS
Brown scientists uncover inner workings of rare eye cells

PROVIDENCE, RI A Brown University team has found that a protein called melanopsin plays a key role in the inner workings of mysterious, spidery cells in the eye called intrinsically photosensitive retinal ganglion cells, or ipRGCs.

Melanopsin, they found, absorbs light and triggers a biochemical cascade that allows the cells to signal the brain about brightness. Through these signals, ipRGCs synchronize the body's daily rhythms to the rising and setting of the sun. This circadian rhythm controls alertness, sleep, hormone production, body temperature and organ function.

Brown researchers, led by neuroscientist David Berson, announced the discovery of ipRGCs in 2002. Their work was astonishing: Rods and cones aren't the only light-sensitive eye cells.

Like rods and cones, ipRGCs turn light energy into electrical signals. But while rods and cones aid sight by detecting objects, colors and movement, ipRGCs gauge overall light intensity. Numbering only about 1,000 to 2,000 out of millions of eyes cells, ipRGCs are different in another way: They have a direct link to brain, sending a message to the tiny region that controls the body clock about how light or dark the environment is. The cells are also responsible for narrowing the pupil of the eye.

"It's a general brightness detection system in the eye," said Berson, the Sidney A. Fox and Dorothea Doctors Fox Professor of Ophthalmology and Visual Sciences. "What we've done now is provide more details about how this system works."

The research, published in the current issue of Nature, provides the first evidence that melanopsin is a functional sensory photopigment. In other words, this protein absorbs light and sets off a chain of chemical reactions in a cell that triggers an electrical response. The study also showed that melanopsin plays this role in ganglion-cell photoreceptors, helping them send a powerful signal to the brain that it is day or night.

The team made
'"/>

Contact: Wendy Lawton
Wendy_Lawton@brown.edu
401-863-1862
Brown University
26-Jan-2005


Page: 1 2

Related biology news :

1. Brown rot shrivels prune production in California
2. Brown cancer biologists identify major player in cell growth
3. Bones in motion: Brown scientists to create new 3-D X-ray system
4. Brown team finds crucial protein role in deadly prion spread
5. Genomic variation easier to identify with UCSD/Brown software
6. Brown scientists map structure of DNA-doctoring protein complex
7. Brown and OTS will jointly manage new ILTER network secretariat
8. Brownfields may turn green with help from Michigan State research
9. NIH grants $11 million to Brown University for cancer research
10. Prions rapidly remodel good protein into bad, Brown study shows
11. Brown-Harvard team solves mobile DNAs surgical sleight-of-hand

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Brown scientists uncover inner workings rare eye cells

(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: